These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21699349)

  • 1. Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz.
    Pelet A; Favrat B; Cavassini M; Eap CB; Besson J; Monnat M
    Am J Drug Alcohol Abuse; 2011 Jul; 37(4):264-8. PubMed ID: 21699349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
    Parienti JJ; Massari V; Rey D; Poubeau P; Verdon R;
    Clin Infect Dis; 2007 Jul; 45(2):263-6. PubMed ID: 17578790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone withdrawal symptoms with nevirapine and efavirenz.
    Pinzani V; Faucherre V; Peyriere H; Blayac JP
    Ann Pharmacother; 2000 Mar; 34(3):405-7. PubMed ID: 10917395
    [No Abstract]   [Full Text] [Related]  

  • 5. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
    Altice FL; Friedland GH; Cooney EL
    AIDS; 1999 May; 13(8):957-62. PubMed ID: 10371177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.
    Dyer KR; Foster DJ; White JM; Somogyi AA; Menelaou A; Bochner F
    Clin Pharmacol Ther; 1999 Jun; 65(6):685-94. PubMed ID: 10391674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone withdrawal when starting an antiretroviral regimen including nevirapine.
    Heelon MW; Meade LB
    Pharmacotherapy; 1999 Apr; 19(4):471-2. PubMed ID: 10212021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nevirapine induces abstinence symptoms in patients on a methadone maintenance program with HIV infection].
    Baño Rodrigo MD; Agujetas Rodríguez M; López García ML; Guillén Llera JL
    Rev Clin Esp; 2000 Jan; 200(1):12-4. PubMed ID: 10721283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.
    Clarke SM; Mulcahy FM; Tjia J; Reynolds HE; Gibbons SE; Barry MG; Back DJ
    Br J Clin Pharmacol; 2001 Mar; 51(3):213-7. PubMed ID: 11298066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.
    Otero MJ; Fuertes A; Sánchez R; Luna G
    AIDS; 1999 May; 13(8):1004-5. PubMed ID: 10371190
    [No Abstract]   [Full Text] [Related]  

  • 12. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methadone withdrawal syndrome induced by nevirapine].
    Bachiller Luque P; Flores AM; de Hoyos Llorente M; Navarro Cañadas C
    Med Clin (Barc); 2000 Mar; 114(10):399. PubMed ID: 10786356
    [No Abstract]   [Full Text] [Related]  

  • 14. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.
    Stocker H; Kruse G; Kreckel P; Herzmann C; Arastéh K; Claus J; Jessen H; Cordes C; Hintsche B; Schlote F; Schneider L; Kurowski M
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4148-53. PubMed ID: 15504834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
    Crauwels HM; van Heeswijk RP; Vandevoorde A; Buelens A; Stevens M; Hoetelmans RM
    J Clin Pharmacol; 2014 Feb; 54(2):133-40. PubMed ID: 24203510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.
    Boffito M; Rossati A; Reynolds HE; Hoggard PG; Back DJ; Di Perri G
    AIDS Res Hum Retroviruses; 2002 Mar; 18(5):341-2. PubMed ID: 11897035
    [No Abstract]   [Full Text] [Related]  

  • 18. Methadone and anti-HIV drugs.
    Fornataro K
    Body Posit; 1999 May; 12(5):13. PubMed ID: 11366305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
    Glasper A; Gossop M; de Wet C; Reed L; Bearn J
    Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.